The Epigenetic Landscape of Malignancy and Chronic Disease

(Cơ chế biểu hiện ngoài gen trong ung thư và bệnh lý mạn tính)

Biên Soạn: ĐV SHPT, BVĐK Gia Đình, Đà Nẵng, VN.



1. How epigenetics manifests in cancer and non-cancerous disease

Epigenetics refers to heritable changes in gene expression that do not alter the underlying DNA sequence. These changes regulate which genes are switched on or off, and when they go awry, they contribute to disease through gene silencing or inappropriate activation.

In cancer, the hallmark pattern is a paradox: global hypomethylation (genome-wide loss of methylation) coexists with focal hypermethylation at specific promoter CpG islands. Hypermethylation silences tumor suppressor genes (like *CDKN2A*, *BRCA1*, *MLH1*), while

hypomethylation activates oncogenes and transposable elements, promoting genomic instability and invasion. Histone marks are similarly disrupted — loss of H4K16 acetylation and H4K20 trimethylation are near-universal in cancer cells.

In non-cancerous disease, the mechanisms are more varied: environmental exposures (stress, diet, toxins) alter methylation and histone marks over time, dysregulating inflammatory pathways, metabolic genes, and neuronal circuits. Unlike in cancer, the epigenetic drift in most non-cancerous diseases tends to be more diffuse rather than locked into a specific gene-silencing pattern.

2. Cancers: methylation study aids diagnosis, treatment, and prognosis

Cancer type	*Key methylation markers*	*Clinical utility*
Glioma / GBM	MGMT promoter methylation	Treatment/Prognosis — predicts response to Temozolomide; methylated = better survival
Colorectal cancer	MLH1 silencing, CIMP panel, SEPT9 cfDNA	Diagnosis/Prognosis — SEPT9 is FDA-cleared blood test; MLH1 guides immunotherapy eligibility
Breast cancer	BRCA1, RASSF1A, APC methylation	Diagnosis/Prognosis — panel aids subtype classification and recurrence risk
Lung cancer	SHOX2, RASSF1A, p16/CDKN2A	Diagnosis — liquid biopsy methylation improves sensitivity in sputum/BAL; early detection
Prostate cancer	GSTP1 (most consistent marker in prostate cancer)	Diagnosis/Prognosis — present in >90% of cases; helps distinguish benign from malignant
Bladder cancer	VIM, TWIST1 methylation in urine cfDNA	Diagnosis — non-invasive urine test for surveillance; reduces cystoscopy burden
Cervical cancer	FAM19A4, CADM1, MAL	Diagnosis — methylation triage of HPV-positive patients; reduces colposcopy referrals
Hepatocellular carcinoma	RASSF1A, APC, SOCS1	Diagnosis/Prognosis — blood-based detection; correlates with Barcelona stage
Liquid biopsy / pan-cancer	Genome-wide cfDNA methylation (Galleri, GRAIL)	Diagnosis — multi-cancer early detection; tissue-of-origin inference from methylation patterns
Hematologic (AML/MDS)	IDH1/2 mutations → aberrant methylation; TET2	Treatment — enasidenib (IDH2i) and ivosidenib (IDH1i) approved; methylation status guides choice

The single most clinically validated and immediately actionable methylation marker is **MGMT promoter methylation in glioblastoma** — it is now standard of care to test before initiating chemotherapy. The pan-cancer liquid biopsy approach (Galleri/GRAIL) is the most ambitious frontier, using genome-wide cfDNA methylation patterns to detect and localize cancers of unknown origin.

3. Non-cancerous diseases: methylation study aids diagnosis, treatment, and prognosis

DISEASE	KEY METHYLATION FINDINGS	CLINICAL UTILITY
Rett syndrome	MeCP2 loss-of-function → global methylation reader dysfunction	Diagnosis/Treatment — definitive genetic/epi genetic diagnosis; MeCP2 gene therapy trials
Fra(X) syndrome	CGG repeat expansion → FMR1 promoter hypermethylation → gene silencing	Diagnosis — methylation-specific PCR is the gold-standard confirmatory test
PW / Angelman	Imprinting defects at 15q11-q13 (SNRPN, UBE3A)	Diagnosis — methylation analysis distinguishes PWS from Angelman and from deletion vs UPD
Systemic lupus (SLE)	DNMT1 downregulation → LINE-1, CD11a, perforin demethylation	Treatment/ Prognosis — methylation scores match with flare activity; DNMT activators under study.
Rheumatoid arthritis	Hypomethylation of CXCL12, IL-6 in synoviocytes	Prognosis — methylation of CXCL12 predicts erosive joint disease severity
Type 2 diabetes mellitus (T2DM)	PPARGC1A, PDX1, TCF7L2 methylation in pancreatic islets	Prognosis — epigenetic clock accelerates in T2DM; islet methylation predicts insulin secretion decline.
Beckwith-Wiedemann/ Silver-Russell syndromes	IGF2/H19 imprinting locus methylation errors	Diagnosis — MS-MLPA is the primary diagnostic tool; surveillance intensity. SEE ADDENDUM***

4. Is methylation the most important epigenetic mark of the four major epigenetic mechanisms?

Methylation is the **best-studied** and **most clinically deployed** mark, but it is not intrinsically more important than the others — it simply has more stable chemistry (it survives formalin fixation, archival tissue, cell-free DNA), making it technically easier to measure in clinical settings.

Here is a side-by-side comparison of all four major epigenetic mechanisms:

DNA METHYLATION	HISTONE MODIFICATION
CHROMATIN REMODELING	NON-CODING RNA (ncRNA) REGULATION

While they are often studied individually, they do not work in isolation. Instead, they operate together like a tightly choreographed orchestra to control whether a gene is accessible and turned "ON" or packed away and turned "OFF."

Here is a clear breakdown of how each of these four mechanisms works, including their common clinical acronyms.

4.1. DNA Methylation

This is the most stable and widely studied epigenetic mark. It acts like a chemical "lock" on the DNA.

- **How it works:** Specialized enzymes add a tiny chemical tag called a methyl group directly to the DNA, usually at spots where a Cytosine base is next to a Guanine base (known as a **CpG site**).
- **The Result:** When a gene's control region (promoter) is heavily crowded with these methyl tags, it physically blocks the cellular machinery from reading the gene. This effectively **silences (turns off)** the gene without changing the underlying genetic code.

4.2. Histone Modification

If DNA is the blueprint, histones are the spools that keep it organized.

- **How it works:** Inside the cell nucleus, six feet of DNA is tightly wrapped around protein spools called **histones**. These histones have little "tails" that can be modified by adding different chemical tags, such as acetyl groups or methyl groups.
- **The Result:** * **Histone Acetylation:** Adding an acetyl group relaxes the spools, opening up the DNA so it can be easily read (**turned ON**).
    - **Histone Methylation:** Depending on the exact location, adding a methyl group usually causes the spools to pack tightly together, hiding the DNA so it cannot be read (**turned OFF**).

4.3. Chromatin Remodeling

This mechanism physically moves the spools to alter DNA access.

- **How it works:** The combination of DNA wrapped around histone spools is called **chromatin**. Chromatin remodeling complexes are molecular motors that use cellular energy to slide, eject, or restructure the histone spools.
- **The Result:** Think of it like moving curtain rings on a rod. By sliding a histone spool out of the way, a previously hidden piece of DNA is suddenly exposed to the surface, allowing the cell to activate that specific gene.

4.4. Non-Coding RNA (ncRNA) Regulation

While the first three mechanisms control whether a gene is copied into RNA, this final mechanism acts as a goalie *after* the RNA is already made.

- **How it works:** Not all RNA in the cell is used to make proteins. A massive amount is **Non-Coding RNA (ncRNA)**, which serves a regulatory role.
- **The Result:** Two major types of ncRNAs act as interceptors:
    - **microRNA (miRNA):** Tiny RNA molecules that bind to target gene messages and destroy them or block them from being translated into protein.
    - **Long Non-Coding RNA (lncRNA):** Larger RNA molecules that act as scaffolding guides, physically recruiting the DNA methylators or histone modifiers directly to specific genes to shut them down.

5. Summary of Essential Epigenetic Acronyms

Here is a quick reference guide to the key acronyms used throughout this text:

- **CpG: C**ytosine-**p**hosphate-**G**uanine (The specific DNA sequence where methylation predominantly occurs).

- **MeCP2** loss-of-function: **Me**thyl-**C**pG-**B**inding **P**rotein **2.** MeCP2 is a crucial epigenetic "Reader" protein. Its job is to bind to methylated DNA and recruit other proteins to lock down chromatin, turning genes off. When a mutation causes a "loss-of-function" (the protein stops working), the cell can no longer silence its target genes. This specific defect is the primary cause of **Rett Syndrome**, a severe X-linked neurodevelopmental disorder that impacts brain development, language, and motor skills.

- **SNRPN, UBE3A:** These two genes sit right next to each other in the imprinted region of Chromosome 15 (15q11-q13). They are the classic targets evaluated by **MS-MLPA** to diagnose Prader-Willi and Angelman syndromes.
  SNRPN = Small **N**uclear **R**ibonucleoprotein **P**olypeptide **N**. This gene is normally active *only* on the chromosome inherited from the father (the maternal copy is epigenetically silenced). If the paternal copy is missing or accidentally silenced, it causes Prader-Willi Syndrome.
  UBE3A = Ubiquitin **P**rotein **L**igase **E3A.** This gene is normally active *only* on the chromosome inherited from the mother in brain tissue. If the maternal copy is missing or epigenetically silenced, it causes Angelman Syndrome.

- **SLE, DNMT1:** SLE = **S**ystemic **L**upus **E**rythematosus. DNMT1 = DNA Methyltransferase 1. In SLE, T-cells often exhibit a significant deficiency or impairment in **DNMT1** activity. Without enough functioning DNMT1, the immune cells experience widespread *hypomethylation* (loss of methyl tags), accidentally turning on pro-inflammatory genes that drive the autoimmune attack.

- **PPARGC1A, PDX1, TCF7L2** methylation: These three genes represent the classic epigenetic signature of Type 2 Diabetes Mellitus (T2DM) and metabolic syndrome. When these genes undergo abnormal methylation, they drive insulin resistance and beta-cell dysfunction.
  PPARGC1A = Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 Alpha. Hypermethylation of this gene reduces energy expenditure and promotes insulin resistance.
  PDX1 = Pancreatic and Duodenal Homeobox 1. Increased methylation silences this gene, impairing the pancreas's ability to secrete insulin.
  TCF7L2 = Transcription Factor 7-Like 2. A major component of the Wnt signaling pathway that regulates blood glucose homeostasis and beta-cell survival. Altered methylation at this locus TCF7L2 is one of the strongest known genetic/epigenetic risk factors for developing Type 2 Diabetes. (Altered in which way, Up or Down? The answer is **both**, because it is site-specific. The *TCF7L2* promoter does not shift in a single uniform direction. Instead, it undergoes **differential methylation**—meaning certain specific CpG sites are turned **up (hypermethylated)** while other specific neighboring sites are turned **down (hypomethyleneated)**. However, when looking at how this drives the pathophysiology of Type 2 Diabetes, the most significant and consistently reported clinical trend is **overall hypermethylation (Up)** at key regulatory points of the promoter)
- AML/MDS: **A**cute **M**yeloid **L**eukemia/ **M**yelodysplastic **S**yndromes, they are tied to mutations in epigenetic "writer" and "eraser" enzymes (like *DNMT3A*, *TET2*, and *IDH1/2*), which cause massive, chaotic DNA methylation across the genome. This specific epigenetic profile makes AML and MDS uniquely vulnerable to **hypomethylating agents** (such as 5-azacytidine and decitabine). These drugs block the aberrant methylation, forcing the malignant cells to either mature normally or self-destruct.
- **Glioblastoma / MGMT**: The most common and aggressive primary malignant brain tumor in adults/ **O^6-M**ethyl**g**uanine-DNA **M**ethyl**t**ransferase. MGMT is a DNA repair enzyme. Its normal job is to fix DNA damage caused by environmental toxins or chemotherapy drugs. **If the MGMT promoter is Hypermethylated (Turned OFF):** The tumor cell cannot repair itself. When the patient is treated with the standard chemotherapy drug **Temozolomide (TMZ)**, the drug easily destroys the tumor's DNA, resulting in a **vastly improved prognosis**. **If the MGMT promoter is Unmethylated (Turned ON):** The tumor actively repairs the damage caused by chemotherapy, rendering the treatment largely ineffective.
- **CRC / CIMP, *MLH1,* PD-1, MSI*:*** ColoRectal Cancer/ CpG Island Methylator Phenotype, MutL Homolog 1, Programmed Cell Death Protein 1, Microsatellite Instability.
- **DNMT: D**NA **M**ethyl**T**ransferase (The family of "writer" enzymes that physically add methyl tags to DNA).
- **TET: T**en-**E**leven **T**ranslocation (The family of "eraser" enzymes responsible for clearing methyl tags away).

- **HAT: H**istone **A**cetyl**t**ransferase (Enzymes that add acetyl tags to histones, opening up chromatin).
- **HDAC: H**istone **De****ac**etylase (Enzymes that remove acetyl tags, causing chromatin to tightly close).
- **ncRNA: N**on-**c**oding **RNA** (The overarching class of RNA molecules that regulate gene expression rather than making proteins).
- **miRNA: m**icro**RNA** (Small non-coding RNAs that silence gene targets by degrading their messages).
- **lncRNA: l**ong **n**on-**c**oding **RNA** (Large non-coding RNAs that guide epigenetic machinery to target chromosomes).
- Both **piRNA** and **siRNA** are highly specialized subclasses of **Non-Coding RNA (ncRNA)**. They fall under the "small RNA" umbrella (usually fewer than 30 nucleotides long) and act as precise genomic weapon systems. Their job is to find matching target sequences and shut them down. However, they protect different parts of the genome and operate in different biological contexts.

  i. siRNA: Short Interfering RNA. Think of siRNA as the cell's **post-transcriptional defense force** against immediate threats, like viral invasions. **Where it comes from:** It is derived from long, double-stranded RNA (dsRNA). This can happen when a virus injects double-stranded RNA into a cell, or when a scientist introduces it artificially in a laboratory. **The Mechanism:** An enzyme called **Dicer** chops this long dsRNA into short pieces (about 21–23 nucleotides long). These short pieces are loaded into a molecular machinery complex called **RISC (RNA-Induced Silencing Complex)**. RISC unzips the double-stranded siRNA, keeps one strand as a guide, and hunts for any matching viral or target mRNA in the cell. When it finds a match, it cuts the mRNA in half, destroying it before it can be made into a protein. **Clinical/Research Importance:** Because scientists can synthesize artificial siRNAs in a lab, we can use them to intentionally "knock down" or turn off almost any disease-causing gene. This therapeutic technique is called **RNA interference (RNAi)**.

  ii. piRNA: Piwi-Interacting RNA. Think of piRNA as the **guardian of hereditary integrity** in germline cells (sperm and egg cells). **Where it comes from:** It is generated from specific, long single-stranded RNA transcripts encoded in the genome, known as piRNA clusters. They are slightly longer than siRNAs (about 26–31 nucleotides). **The Mechanism:** Instead of binding to the RISC complex, they bind exclusively to a specific family of proteins called **Piwi proteins** (hence the name *Piwi-interacting*). **The Primary Mission:** Their main job is to silence **transposons** (also called "jumping genes"). Transposons are selfish DNA sequences that like to copy and paste themselves randomly across the genome. If they jump into a vital gene during sperm or egg development, they can cause catastrophic mutations or infertility. piRNAs find these transposons and neutralize them by cutting their RNA or by physically recruiting **DNMTs (DNA Methyltransferases)** to permanently lock down the transposon DNA with methyl tags.

  iii. **Key Differences at a Glance**

• **Feature**	• **siRNA (Short Interfering RNA)**	• **piRNA (Piwi-Interacting RNA)**
• **Primary Location**	Somatic cells (body cells) and germ cells; highly conserved across plants and animals.	Predominantly restricted to the germline (testes and ovaries) to protect future generations.
• **Origin Structure**	Cut down from **double-stranded** RNA precursors.	Processed from long **single-stranded** RNA clusters.
• **Key Protein Partner**	Works alongside the **Argonaute** protein family inside the **RISC** complex.	Works exclusively with the **Piwi** subfamily of proteins.

• **Feature**	• **siRNA (Short Interfering RNA)**	• **piRNA (Piwi-Interacting RNA)**
• **Main Target**	Viruses and specific gene transcripts (mRNA destruction).	Transposons/Jumping genes (epigenetic silencing and RNA destruction).
• **Dicer Dependent?**	**Yes**. Requires the Dicer enzyme to chop it to size.	**No**. Its processing bypasses the Dicer enzyme entirely.

6. Effective tools for epigenetic study:

6.1. Diagnostic tools

Pyrosequencing (bisulfite)	Quantitative single-locus methylation at CpG sites. Gold standard for MGMT, SEPT9, MLH1 in routine pathology labs.	Routine
MSP / qMSP	Methylation-specific PCR: fast, cheap, binary or semi-quantitative. Used for GSTP1 (prostate), SHOX2 (lung BAL), FAM19A4 (cervical).	Routine
Whole-genome bisulfite seq (WGBS)	Single-base resolution across entire genome. Research and complex diagnostics; increasingly used for methylation-based CNS tumor classification (WHO 2021).	Emerging
450K / EPIC array (Illumina)	850,000 CpG sites genome-wide. Backbone of Heidelberg Brain Tumor Classifier (WHO 2021 standard) and epigenetic clock computation. Clinical in neuro-oncology.	Routine (neuro)
cfDNA methylation (liquid biopsy)	Circulating tumor DNA methylation in plasma. Galleri (GRAIL) detects 50+ cancer types; Epi proColon (SEPT9) FDA-cleared for colorectal. Most promising non-invasive cancer detection.	FDA-cleared (CRC) / trial (pan-cancer)
ChIP-seq (histone marks)	Chromatin immunoprecipitation + sequencing maps histone marks genome-wide. Research standard; emerging for lymphoma subtyping (H3K27me3 profiling).	Research / emerging
ATAC-seq (chromatin access)	Maps open chromatin regions (Tn5 transposase). Reflects combined effect of all remodeling complexes. Single-cell ATAC-seq enables tumor heterogeneity mapping.	Research
serum/plasma miRNA profiling	qPCR or small RNA-seq panels. miR-21, miR-155, miR-141 panels used for breast, prostate, colon screening in research. Not yet FDA-cleared as standalone.	Emerging

6.2. Treatment tools (epigenetic drugs)

DNMT inhibitors (DNMTi)	Azacitidine (5-azaC), decitabine, cedazuridine. Reactivate silenced tumor suppressors. Approved for MDS, AML, CMML. Also studied in autoimmune disease.	FDA-approved
HDAC inhibitors (HDACi)	Vorinostat, romidepsin (T-cell lymphoma), panobinostat (myeloma), belinostat. Reactivate silenced genes by restoring histone acetylation. Many in trials for solid tumors.	FDA-approved
EZH2 inhibitors	Tazemetostat: FDA-approved for EZH2-mutant follicular lymphoma and epithelioid sarcoma (SMARCB1-loss). Targets H3K27me3. Synthetic lethal in SWI/SNF-mutant tumors.	FDA-approved
IDH1/2 inhibitors	Enasidenib (IDH2), ivosidenib (IDH1), olutasidenib. IDH mutations → 2-HG → TET2 inhibition → hypermethylation. Approved for AML; ivosidenib approved for IDH1-mutant cholangiocarcinoma.	FDA-approved
BET bromodomain	JQ1 (research), BMS-986158, ZEN-3694. Block BRD4 reading of acetylated histones → suppress MYC. Phase II trials for NUT carcinoma, TNBC, prostate.	Phase II/III

inhibitors		
LSD1/KDM1A inhibitors	Iadademstat, tranylcypromine analogs. Inhibit H3K4me1/2 demethylation → block enhancer activity. Trials in AML, SCLC. Iadademstat + azacitidine in MDS.	Phase I/II
PRMT5 inhibitors	Arginine methyltransferase inhibition. Synthetic lethal in MTAP-deleted tumors (~15% of all cancers). Multiple phase II trials (GSK3326595, JNJ-64619178).	Phase II

6.3. Prognostic and monitoring tools:

Epigenetic clocks (Horvath/PhenoAge)	450K/EPIC array methylation at 353–513 CpG sites computes biological age. Epigenetic age acceleration predicts mortality, cancer risk, dementia independently of chronological age.	Clinical research
MRD by cfDNA methylation	Post-treatment ctDNA methylation surveillance for Minimal Residual Disease, better than protein markers for some cancers (CRC, Breast).	Clinical trials
Heidelberg brain tumor classifier	EPIC array on FFPE tumor tissue → machine-learning classifier → 100+ CNS tumor types. WHO 2021 CNS classification.	CNS WHO standard
Immune epigenomics	Methylation-based immune cell deconvolution (EpiDISH, MethylCIBERSORT) from bulk tissue. Predicts immunotherapy response better than gene expression in some cohorts.	Research

7. The most immediately useful tools by context:

For a solid tumor (brain, lung, breast, colon): bisulfite pyrosequencing or MSP for specific markers (MGMT, MLH1, GSTP1), supplemented by Illumina EPIC array for CNS tumors. Treatment with DNMTi or HDACi is well-established in hematologic malignancy; for solid tumors, targeted epigenetic therapy depends on the specific mutation (IDH1/2, EZH2, SMARCA4 status).

For hematologic malignancy: IDH1/2 testing with targeted inhibitors has transformed AML management; HDAC inhibitors are standard in cutaneous T-cell lymphoma; MDS/AML routinely uses azacitidine/decitabine.

For non-cancer diagnosis: methylation testing is the gold standard for imprinting disorders (PWS/AS, BWS) and Fragile X — it is not optional in these workups. For autoimmune and metabolic disease, methylation biomarkers are still largely research tools, though epigenetic clock acceleration is entering risk stratification in clinical trials.

The future lies in cfDNA methylation — it offers tissue-of-origin inference, multi-cancer early detection, and MRD surveillance from a single blood draw, without biopsy. GRAIL's Galleri test represents the most ambitious clinical deployment of this principle to date.

8. Cancers most heavily driven by DNA methylation changes:



Here is a deeper look at the most important patterns across these cancer types.

8.1. The **universal paradox**: hypermethylation + hypomethylation in the same tumor

Every cancer on this list simultaneously carries both patterns, which initially seems contradictory. The explanation is that they target different genomic locations and serve different oncogenic purposes:

Focal hypermethylation at promoter CpG islands silences specific tumor suppressor genes — it acts like a "lock" preventing the cell's brakes from engaging. The silenced genes (*CDKN2A*, *RASSF1A*, *MLH1*, *BRCA1*) would normally restrain proliferation, trigger apoptosis, or repair DNA damage.

Global hypomethylation across repetitive elements (especially LINE-1 and SINE retrotransposons, which make up ~45% of the genome) removes a genome-wide "silencing blanket," causing chromosomal instability, activation of transposable elements, and de-repression of oncogenes. The ...



PATHWAYS TO MISMATCH REPAIR DEFICIENCY IN CRC

... degree of LINE-1 hypomethylation is actually a reasonably consistent biomarker of aggressive behavior across many tumor types.

8.2. The five most clinically important cancer-methylation relationships

AML/MDS is arguably the field's greatest success story. The discovery that IDH1/2 mutations cause hypermethylation through 2-hydroxyglutarate accumulation directly led to targeted drugs (enasidenib,

ivosidenib) now approved as front-line agents. DNMTi (azacitidine, decitabine) are standard of care and work by reactivating silenced tumor suppressors in the malignant clone.

Glioblastoma / MGMT is the single most actionable individual methylation biomarker. A methylated *MGMT* promoter silences the DNA-repair enzyme that would otherwise "undo" the damage caused by temozolomide alkylation — so methylated tumors cannot repair the drug's damage, and patients live significantly longer. Testing is now mandatory before starting chemotherapy.

CRC / CIMP defined an entirely new tumor subtype. CIMP-high colorectal cancers silence *MLH1*, lose DNA mismatch repair, and accumulate thousands of mutations that are highly visible to the immune system — making them the most responsive solid tumors to PD-1 checkpoint inhibitors. This pathway from methylation → MSI → immunotherapy sensitivity is now a textbook clinical algorithm.

Cervical / HPV triage is the most promising emerging clinical application. When HPV infection is detected, methylation of *FAM19A4* and *CADM1* identifies women whose infection has already caused epigenetic damage predictive of progression — allowing targeted colposcopy rather than treating every HPV-positive woman as high-risk.

Pan-cancer cfDNA methylation (Galleri/GRAIL) represents the most transformative future direction. Because each tissue type has a characteristic methylation signature, circulating tumor DNA in the blood carries the "return address" of its tissue of origin. A single blood draw can detect signals from 50+ cancer types simultaneously — something no protein biomarker panel can do — and crucially, it can localize the likely primary site when a signal is found.

9. Epigenomic influence on neurological & psychiatric disorders

Epigenetic mechanisms are uniquely critical in the central nervous system because neurons are post-mitotic (they do not divide), meaning they must rely heavily on dynamic chromatin remodeling and DNA modifications to adapt to lifelong environmental stimuli, store memories, and regulate behavior.

When these mechanisms fail, they manifest as either neurodevelopmental/neurodegenerative conditions (neurological) or maladaptive stress responses (psychiatric).

9.1. Neurological Disorders: Structural and Cellular Decay

In neurology, epigenetic pathology typically involves structural defects in "reader" or "writer" proteins, or progressive gene silencing that leads to neurodegeneration.

i. Neurodevelopmental Single-Gene Defects

- **Rett Syndrome (*MeCP2* mutation):** As noted earlier, losing the "reader" protein **MeCP2** means the brain cannot downregulate specific genes during development. This disrupts synaptic maturation and dendritic branching, leading to severe cognitive and motor regression.
- **Fragile X Syndrome (*FMR1* hypermethylation):** Triplet repeat expansions recruit **DNMTs**, causing extensive promoter hypermethylation. This completely silences the Fragile X Mental

Retardation Protein (FMRP), which is essential for normal synaptic plasticity (the ability of synapses to strengthen or weaken over time).

ii. Neurodegenerative Diseases

- **Alzheimer's Disease (AD):** The AD brain exhibits widespread alterations in both DNA methylation and histone modifications. Specifically, hypermethylation and histone deacetylation (driven by overactive **HDACs**) silence neuroprotective factors and neurogenesis-related genes like **BDNF** (Brain-Derived Neurotrophic Factor). Concurrently, hypomethylation at the *APP* (Amyloid Precursor Protein) gene promoter accelerates amyloid-beta plaque accumulation.
- **Huntington's Disease (HD):** The mutant huntingtin protein physically binds to and inhibits **HATs** (Histone Acetyltransferases). This tips the cellular balance in favor of histone deacetylation, causing widespread chromatin compaction. Vital neuroprotective genes are locked away, accelerating striatal neuronal death.

9.2. Psychiatric Disorders: Environmental Vulnerability & Stress

In psychiatry, epigenetics, in traumatic or environmental events, triggers biochemical reactions that alter the epigenetic map of the brain, modifying a person's vulnerability to psychiatric conditions.

i. Major Depressive Disorder (MDD) & Early Life Trauma

- **The HPA** (Hypothalamic-Pituitary-Adrenal) **Axis Dysregulation:** Severe early life stress or childhood trauma triggers long-term hypermethylation of the **NR3C1** gene (which encodes the glucocorticoid receptor in the hippocampus).
- **The Clinical Consequence:** Because the hippocampus lacks functional glucocorticoid receptors, the body loses its negative feedback loop for stress. The **HPA** axis remains hyperactive, pumping out cortisol continuously. This chronic stress state chemically alters the brain, predisposing the individual to MDD and anxiety disorders in adulthood.

ii. Schizophrenia & Bipolar Disorder

- **GABAergic Silencing:** Post-mortem brain tissue of patients with schizophrenia reveals intense hypermethylation of the promoter region for **RELN** (Reelin, a protein critical for neuronal migration and synaptic positioning) and **GAD1** (an enzyme essential for manufacturing GABA, the brain's primary inhibitory neurotransmitter).
- **The Clinical Consequence:** This targeted silencing disrupts the delicate balance between excitation and inhibition in the prefrontal cortex, driving the cognitive deficits, working memory issues, and psychosis characteristic of the disease.

iii. Substance Use Disorders (SUD)

- **Chromatin Remodeling in Addiction:** Chronic exposure to drugs of abuse (like cocaine or alcohol) induces acute histone acetylation in the brain's reward center, specifically the **NAc** (Nucleus Accumbens).
- **The Clinical Consequence:** This opens up chromatin loops, rapidly transcriptionally priming genes like . This structural rearrangement reinforces rewarding memories and causes permanent changes in dendritic spine density, driving compulsion and long-term relapse risk.

Summary of Psychiatric & Neurological Acronyms

- **BDNF: B**rain-**D**erived **N**eurotrophic **F**actor (A protein crucial for the survival and growth of neurons).
- **HPA Axis: H**ypothalamic-**P**ituitary-**A**drenal Axis (The complex feedback system regulating the body's response to stress).
- **NR3C1: N**uclear **R**eceptor Subfamily **3** Group **C** Member **1** (The gene encoding the glucocorticoid receptor).
- **GAD1: G**lutamic **A**cid **D**ecarboxylase **1** (The enzyme that synthesizes the neurotransmitter GABA).
- **NAc: N**ucleus **A**ccumbens (The primary cognitive processing center for reward, pleasure, and addiction in the brain).

10. The core logic: why the brain is especially epigenetically vulnerable

10.1. Three features make the nervous system uniquely susceptible to epigenetic disruption.

First, neurons are essentially post-mitotic for life. Unlike cancer cells that divide and propagate new epigenetic errors, neurons must maintain their identity — and their gene expression programs — for decades without the "reset" that cell division provides. This means epigenetic changes are both more durable and more damaging in neurons than in most other tissues.

Second, neuronal identity is itself epigenetically encoded. A cortical excitatory neuron, a dopaminergic neuron, and a cerebellar Purkinje cell share identical DNA sequences but radically different epigenomes. Each cell type's identity is maintained by a self-reinforcing system of transcription factors, histone marks, and DNA methylation patterns. Perturb this system and the cell loses its functional identity — which is exactly what happens in schizophrenia's cortical interneurons and Alzheimer's hippocampal cells.

Third, synaptic plasticity — the molecular basis of memory and learning — is inherently epigenetic. Long-term potentiation (LTP) requires persistent changes in gene expression at synapses, and these changes are maintained by histone acetylation and DNA methylation at the relevant promoters. This

means every memory you form involves a small epigenetic modification. It also means that epigenetic dysregulation can directly impair or distort memory and emotional learning.

10.2. The three most clinically significant discoveries

NR3C1 methylation from early life adversity is the most consequential finding for psychiatry. Seminal work by Michael Meaney's group showed that rat pups receiving low maternal care had higher methylation at the NR3C1 glucocorticoid receptor promoter in their hippocampus — measurable in adulthood, associated with stress hyperreactivity, and reversible by intracerebroventricular infusion of methionine or HDAC inhibitors. In humans, childhood abuse specifically methylates NR3C1 exon 1F in the hippocampus, with a suicide-specific methylation signature identifiable in post-mortem brain tissue. This mechanistically connects adverse childhood experiences to measurable biological risk for depression, PTSD, and HPA dysregulation — and is among the first times epigenetics has provided a biological mechanism for social experience causing lasting mental illness.

DeltaFosB and addiction demonstrated that the reward circuit can be epigenetically "locked" into a drug-seeking state by repeated exposure. DeltaFosB is a stable transcription factor isoform that accumulates with each drug exposure, recruits HDAC and HAT complexes to hundreds of reward genes, and persists far longer than the drug itself — potentially months after cessation. This explains withdrawal, craving, and relapse at a molecular level, and has guided interest in HDAC inhibitors and G9a inhibitors as anti-relapse agents.

Intergenerational transmission of stress has fundamentally changed how we think about mental illness inheritance. Epigenetic changes from parental stress — encoded in sperm piRNAs and small RNA fractions — can reprogram the developing brain's stress-response architecture in offspring, without any genetic change. This provides a plausible mechanism for why the children of trauma survivors have elevated rates of anxiety and PTSD even without direct exposure to the traumatic event, and opens entirely new preventive intervention points.

10.3. The convergence point: BDNF

Across nearly every disorder in this framework — depression, PTSD, Alzheimer's, Huntington's, schizophrenia, addiction — epigenetic silencing of *BDNF* (brain-derived neurotrophic factor) is a recurring theme. BDNF exon IV is hypermethylated by chronic stress, by mutant huntingtin's, by DNMT1 overactivity in schizophrenia, and by aging. This convergence suggests that maintaining epigenetic accessibility at neuroplasticity genes — especially BDNF — is a fundamental challenge for the brain, and that interventions restoring it (exercise, ketamine, HDAC inhibitors) may work partly through a shared mechanism regardless of the initiating disease.

11. CONCLUSION:



When Watson and Crick described the double helix, heredity seemed settled: destiny written in four letters, fixed at conception. Epigenetics has replaced that blueprint with something far more dynamic. The genome is not a script but a vast library — and epigenetics is the librarian, deciding which books are opened and which remain sealed, responding continuously to environment, experience, and age.

Four molecular systems carry out this work. DNA methylation places chemical locks on gene promoters, silencing them without altering a single base of sequence. Histone modification rewrites the physical accessibility of the genome, opening chromatin for transcription or compacting it into silence. Non-coding RNAs fine-tune gene expression with remarkable precision. Chromatin remodeling complexes — mutated in roughly one in five cancers — physically reposition the packaging proteins that determine what transcriptional machinery can reach. Together they form an interlocked regulatory network of extraordinary complexity, exquisitely sensitive to diet, stress, toxins, and social experience.

In cancer, this network fails in recognizable and now clinically actionable ways. MGMT methylation testing guides chemotherapy decisions in glioblastoma as standard of care. IDH1/2 mutations, which hijack the methylation machinery in leukemia, are targeted by FDA-approved drugs. A blood test reading SEPT9 methylation detects colorectal cancer non-invasively. The Heidelberg Brain Tumor Classifier resolves diagnoses that microscopy cannot. Pan-cancer liquid biopsy — inferring tumor type from the methylation signature of circulating DNA — may become the most consequential cancer screening advance of this generation.

In non-cancerous disease, the story is quieter but equally profound. Fragile X and Rett syndromes are not missing genes — they are silenced or misread ones, the code intact but the librarian's lock

engaged. Imprinting disorders turn on which parent's methylation marks are intact. Lupus arises when the machinery maintaining methylation fails and the immune system misreads its own manual. The epigenetic clock, calibrated from hundreds of CpG sites, now predicts biological age, mortality, and dementia risk more accurately than chronological age alone.

Nowhere is the story more humanly significant than in the brain. That early childhood adversity methylates the glucocorticoid receptor gene in the hippocampus — programming a lifelong hyperactive stress response from the quality of care received in infancy — is one of the most striking findings in modern medicine. It gives molecular substance to what clinicians have long observed: the social environment of early life is not merely formative in some vague sense, but literally inscribed into the biochemistry of developing neurons. BDNF silencing threads through depression, Alzheimer's disease, Huntington's disease, schizophrenia, and addiction — suggesting that maintaining epigenetic access to neuroplasticity genes is one of the brain's most fundamental and most frequently failing challenges.

Yet the most important word in epigenetics medicine is also its most hopeful: reversible. A genetic mutation is permanent; an epigenetic mark can be erased. Azacitidine reactivates silenced tumor suppressors in leukemia. EZH2 inhibitors dissolve Polycomb-mediated gene silencing in lymphoma and, experimentally, restore remyelination in multiple sclerosis. Ketamine resets histone acetylation at synaptic plasticity genes within hours. Exercise reverses stress-induced BDNF silencing within weeks. MeCP2 gene therapy trials are working to restore the protein that Rett syndrome cannot produce. The therapeutic toolkit is still young, but its direction is clear.

We are living through the early stages of a medicine that could not have been imagined fifty years ago, because it rests on understanding that our genome is not a fixed destiny but a richly annotated, continuously updated manuscript — marked up by evolution, shaped by development, and rewritten by every significant experience we have. Science is learning to read those annotations. More slowly, but unmistakably, it is learning to edit them. That may prove to be one of the most consequential insights in the history of human health.

12. REFERENCES:

[1] Cavalli G, Heard E. Advances in epigenetics link genetics to the environment and disease. Nature. 2019 Jul;571(7766):489-499. doi: 10.1038/s41586-019-1411-0. Epub 2019 Jul 24. PMID: 31341302. General✓ verifiedCited at: §1 (epigenetic mechanisms overview); §4 (mark comparison)

https://pubmed.ncbi.nlm.nih.gov/31341302/

[2] Jones, P. A., & Baylin, S. B. (2007). The Epigenomics of Cancer. *Cell*, *128*(4), 683-692. https://doi.org/10.1016/j.cell.2007.01.029 General✓ verifiedCited at: §1 (cancer paradox: hyper + hypomethylation); §2 (cancer methylation table) https://pure.johnshopkins.edu/en/publications/the-epigenomics-of-cancer-3/

[3] Horvath, S., & Raj, K. (2018). DNA methylation-based biomarkers and the epigenetic clock theory of ageing. *Nature Reviews Genetics*, *19*(6), 371-384. https://doi.org/10.1038/s41576-018-0004-3 General✓ verifiedCited at: §3 (epigenetic clocks); §5 (tools — Horvath/PhenoAge clocks) https://www.nature.com/articles/s41576-018-0004-3

[4] Molina-Serrano, D., Kyriakou, D., & Kirmizis, A. (2019). Histone Modifications as an Intersection Between Diet and Longevity. *Frontiers in Genetics*, *10*, 192. https://doi.org/10.3389/fgene.2019.00192 General✓ verifiedCited at: §4 (histone modification mechanisms — HAT/HDAC/HMT) https://pmc.ncbi.nlm.nih.gov/articles/PMC6422915/

[5] Palazzo AF, Lee ES. Non-coding RNA: what is functional and what is junk? Front Genet. 2015 Jan 26;6:2. doi: 10.3389/fgene.2015.00002. PMID: 25674102; PMCID: PMC4306305. General✓ verifiedCited at: §4 (ncRNA mechanisms — miRNA, lncRNA, piRNA) https://pubmed.ncbi.nlm.nih.gov/25674102/

[6] Kadoch, C., & Crabtree, G. R. (2015). Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. *Science Advances*, *1*(5), e1500447. https://doi.org/10.1126/sciadv.1500447 General✓ verifiedCited at: §4 (chromatin remodeling — SWI/SNF, ARID1A, SMARCA4) https://pmc.ncbi.nlm.nih.gov/articles/PMC4640607/

[7] Hegi ME et al., *MGMT* Gene Silencing and Benefit from Temozolomide in Glioblastoma, New England Journal of Medicine. 2005;352(10):997–1003. Cancer✓ verifiedCited at: §2 (cancer table: glioblastoma/MGMT); §5 (MGMT as most actionable marker) doi.org/10.1056/NEJMoa043331

[8] Weisenberger DJ, et al., CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006 Jul;38(7):787-93. doi: 10.1038/ng1834. Epub 2006 Jun 25. PMID: 16804544. Cancer✓ verifiedCited at: §2 (cancer table: colorectal/CIMP); §5 (CIMP → MSI → immunotherapy) https://pubmed.ncbi.nlm.nih.gov/16804544/

[9] Church TR, Wandell M, Lofton-Day C*, et al,* Prospective evaluation of methylated *SEPT9* in plasma for detection of asymptomatic colorectal cancer. *Gut* 2014;**63:**317-325. Cancer✓ verifiedCited at: §2 (cancer table: colorectal SEPT9 FDA-cleared); §5 (cfDNA liquid biopsy) https://gut.bmj.com/content/63/2/317

[10] Lee WH, et al., Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11733-7. doi: 10.1073/pnas.91.24.11733. PMID: 7972132; PMCID: PMC45306. Cancer✓ verifiedCited at: §2 (cancer table: prostate/GSTP1); §5 (>90% prostate cancers) https://pubmed.ncbi.nlm.nih.gov/7972132/

[11] Gorovets D, Kannan K, Shen R, Kastenhuber ER, Islamdoust N, Campos C, Pentsova E, Heguy A, Jhanwar SC, Mellinghoff IK, Chan TA, Huse JT. IDH mutation and neuroglial developmental features

define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res. 2012 May 1;18(9):2490-501. doi: 10.1158/1078-0432.CCR-11-2977. Epub 2012 Mar 13. PMID: 22415316. Cancer⚠ Cited at: §2 (cancer table: AML/IDH mutations); §5 (IDH → 2-HG → TET inhibition) https://pubmed.ncbi.nlm.nih.gov/22415316/

[12] Ye, D., Xiong, Y., & Guan, K. L. (2012). The mechanisms of IDH mutations in tumorigenesis. *Cell Research*, *22*(7), 1102. https://doi.org/10.1038/cr.2012.51 Cancer✓ verified Cited at: §2 (cancer table: AML/IDH); §5 (IDH pathway — 2-HG mechanism) https://pmc.ncbi.nlm.nih.gov/articles/PMC3391014/

[13] De Strooper LM, Meijer CJ, Berkhof J, Hesselink AT, Snijders PJ, Steenbergen RD, Heideman DA. Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions. Cancer Prev Res (Phila). 2014 Dec;7(12):1251-7. doi: 10.1158/1940-6207.CAPR-14-0237. Epub 2014 Oct 3. PMID: 25281488. Cancer✓ verified Cited at: §2 (cancer table: cervical/FAM19A4); §5 (cervical triage) https://pubmed.ncbi.nlm.nih.gov/25281488/

[14] Bettegowda C, et al., Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094. PMID: 24553385; PMCID: PMC4017867. Cancer✓ verified Cited at: §2 (cancer table: liquid biopsy/pan-cancer cfDNA) https://pubmed.ncbi.nlm.nih.gov/24553385/

[15] Thomas F. Imperiale, M.D., Kyle Porter, M.A.S., Julia Zella, Ph.D., Zubin D. Gagrat, B.S., Marilyn C. Olson, Ph.D., Sandi Statz, M.S., Jorge Garces, Ph.D., **+6** BLUE-C Study Investigators. **Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening**. **New England Journal of Medicine**, **Volume 390 • Number 11 • March 14, 2024**, **Pages: 984-993.** Cancer⚠ Cited at: §5 (tools: cfDNA methylation for multi-cancer detection). https://www.nejm.org/doi/full/10.1056/NEJMoa2310336#core-r1-1

[16] Capper D, et al., DNA methylation-based classification of central nervous system tumours. Nature. 2018 Mar 22;555(7697):469-474. doi: 10.1038/nature26000. Epub 2018 Mar 14. PMID: 29539639; PMCID: PMC6093218. Cancer✓ verified Cited at: §2 (cancer table: glioma/Heidelberg classifier); §5 (tools: EPIC array/WHO 2021). https://pubmed.ncbi.nlm.nih.gov/29539639/

[17] Fraga MF, et al., Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005 Apr;37(4):391-400. doi: 10.1038/ng1531. Epub 2005 Mar 13. PMID: 15765097. Cancer✓ verified Cited at: §1 (histone mark disruption in cancer); §4 (histone marks table: H4K16ac loss). https://pubmed.ncbi.nlm.nih.gov/15765097/

[18] McCabe MT, et al., EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012 Dec 6;492(7427):108-12. doi: 10.1038/nature11606. Epub 2012 Oct 10. PMID: 23051747. Cancer✓ verified Cited at: §5 (tools: EZH2 inhibitor tazemetostat). https://pubmed.ncbi.nlm.nih.gov/23051747/

[19] McGowan PO, et al., Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci. 2009 Mar;12(3):342-8. doi: 10.1038/nn.2270. PMID:

19234457; PMCID: PMC2944040. Non-cancer✓ verified Cited at: §3 (non-cancer table: PTSD/NR3C1); §6 (NR3C1 methylation from adversity). https://pubmed.ncbi.nlm.nih.gov/19234457/

[20] Meaney MJ. Maternal care, gene expression, and the transmission of individual differences in stress reactivity across generations. Annu Rev Neurosci. 2001;24:1161-92. doi: 10.1146/annurev.neuro.24.1.1161. PMID: 11520931. Non-cancer✓ verified Cited at: §3 (non-cancer table: SLE/autoimmune); §6 (early life adversity / NR3C1 methylation) https://pubmed.ncbi.nlm.nih.gov/11520931/

[21] Radtke KM, Ruf M, Gunter HM, Dohrmann K, Schauer M, Meyer A, Elbert T. Transgenerational impact of intimate partner violence on methylation in the promoter of the glucocorticoid receptor. Transl Psychiatry. 2011 Jul 19;1(7):e21. doi: 10.1038/tp.2011.21. PMID: 22832523; PMCID: PMC3309516. Non-cancer✓ verified Cited at: §6 (intergenerational transmission of stress — Holocaust survivor offspring). https://pubmed.ncbi.nlm.nih.gov/22832523/

[22] Klengel T et al., Allele-specific FKBP5 DNA demethylation mediates gene–childhood trauma interactions, nature NEUROSCIENCE VOLUME 16 | NUMBER 1 | JANUARY 2013, p. 33–44. Non-cancer✓ verified Cited at: §3 (non-cancer table: PTSD/FKBP5); §6 (PTSD section — FKBP5 mechanism). https://www.psychiatry.wisc.edu/courses/Nitschke/seminar/Klengel%20et%20al,%20Nat%20Neurosci%2016,%202013.pdf

[23] Sun H, Kennedy PJ, Nestler EJ. Epigenetics of the depressed brain: role of histone acetylation and methylation. Neuropsychopharmacology. 2013 Jan;38(1):124-37. doi: 10.1038/npp.2012.73. Epub 2012 Jun 13. PMID: 22692567; PMCID: PMC3521990. Non-cancer✓ verified Cited at: §6 (depression/HDAC5; BDNF exon IV methylation). https://pubmed.ncbi.nlm.nih.gov/22692567/

[24] Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008 May 30;320(5880):1224-9. doi: 10.1126/science.1153252. PMID: 18511691; PMCID: PMC2443785. Non-cancer✓ verified Cited at: §6 (neurodevelopmental: Rett syndrome/MeCP2). https://pubmed.ncbi.nlm.nih.gov/18511691/

[25] Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT, Saxe D, Warren ST. DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet. 1992 Sep;1(6):397-400. doi: 10.1093/hmg/1.6.397. PMID: 1301913. Non-cancer⚠ Cited at: §3 (non-cancer table: Fragile X); §6 (neurodevelopmental: FMR1). https://pubmed.ncbi.nlm.nih.gov/1301913/

[26] Siu MT, Weksberg R. Epigenetics of Autism Spectrum Disorder. Adv Exp Med Biol. 2017;978:63-90. doi: 10.1007/978-3-319-53889-1_4. PMID: 28523541. Non-cancer⚠ Cited at: §6 (neurodevelopmental). https://pubmed.ncbi.nlm.nih.gov/28523541/

[27] Alves, V. C., Carro, E., & Figueiro-Silva, J. (2024). Unveiling DNA methylation in Alzheimer's disease: A review of array-based human brain studies. *Neural Regeneration*

Research, *19*(11), 2365. https://doi.org/10.4103/1673-5374.393106. Neuro/psych✓ verified Cited at: §6 (neurological: Alzheimer's/ANK1, DUSP22). https://pmc.ncbi.nlm.nih.gov/articles/PMC11090417/

[28] Arnaud Van Den Broeck, Elisabeth Brambilla, et al.; Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non–Small Cell Lung Cancer. *Clin Cancer Res* 15 November 2008; 14 (22): 7237–7245. https://doi.org/10.1158/1078-0432.CCR-08-0869. Neuro/psych⚠ Cited at: §4 (histone mark table: H4K16ac global loss in cancer). https://aacrjournals.org/clincancerres/article/14/22/7237/73167/Loss-of-Histone-H4K20-Trimethylation-Occurs-in

[29] Matsumoto, L., Takuma, H., Tamaoka, A., Kurisaki, H., Date, H., Tsuji, S., & Iwata, A. (2010). CpG Demethylation Enhances Alpha-Synuclein Expression and Affects the Pathogenesis of Parkinson's Disease. *PLOS ONE*, *5*(11), e15522. https://doi.org/10.1371/journal.pone.0015522. Neuro/psych✓ verified Cited at: §6 (neurological: Parkinson's/SNCA hypomethylation). https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0015522

[30] Glajch KE, Sadri-Vakili G. Epigenetic Mechanisms Involved in Huntington's Disease Pathogenesis. J Huntingtons Dis. 2015;4(1):1-15. doi: 10.3233/JHD-159001. PMID: 25813218. Neuro/psych✓ verified Cited at: §6 (neurological: Huntington's/H3K4me3, CBP, REST). https://pubmed.ncbi.nlm.nih.gov/25813218/

[31] Moraitis, S., & Piperi, C. (2025). Multi-Faceted Role of Histone Methyltransferase Enhancer of Zeste 2 (EZH2) in Neuroinflammation and Emerging Targeting Options. *Biology*, *14*(7), 749. https://doi.org/10.3390/biology14070749 Neuro/psych⚠ Cited at: §6 (neurological: MS remyelination/EZH2 block). https://pmc.ncbi.nlm.nih.gov/articles/PMC12292988/

[32] Guidotti A, Grayson DR, Caruncho HJ. Epigenetic RELN Dysfunction in Schizophrenia and Related Neuropsychiatric Disorders. Front Cell Neurosci. 2016 Apr 5;10:89. doi: 10.3389/fncel.2016.00089. PMID: 27092053; PMCID: PMC4820443. Neuro/psych✓ verified Cited at: §6 (psychiatric: schizophrenia/RELN, GAD1, DNMT1). https://pubmed.ncbi.nlm.nih.gov/27092053/

[33] The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium (PGC): overall coordination: P.V.G. Coordination of statistical analyses: M.J.D. Coordination of phenotypic analyses: K.S.K. Statistical analyses: S.R., M.J.D., P.A.H., D.-Y.L., S.P., F.D., B.M.N., L.R., P.M.V., D.P., D.M.R. Manuscript preparation: P.V.G. (primary), M.J.D. (primary), A.R.S. (primary), S.R. (primary), M.C.O. (primary), K.S.K., D.F.L., P.S., P.A.H., P.F.S. (primary), D.-Y.L., J.D., R.A.O., O.A.A., E. Scolnick. Phenotypic analyses: K.S.K., A.F., A.C., R.L.A., et al., GENOME-WIDE ASSOCIATION STUDY IDENTIFIES FIVE NEW SCHIZOPHRENIA LOCI. 2011, Nat Genet. ; 43(10): 969–976. © 2011 Nature America, Inc. All rights reserved. https://www.researchgate.net/publication/220839295_Genome-wide_association_study_identifies_five_new_schizophrenia_loci. Neuro/psych✓ verified Cited at: §6 (psychiatric: schizophrenia/GWAS). file:///C:/Users/Hi/Desktop/ĐV%20SHPT/Genome-wideassociationstudyidentifiesfivenewschizophrenialoci.pdf

[34] McClung CA. Role for the Clock gene in bipolar disorder. Cold Spring Harb Symp Quant Biol. 2007;72:637-44. doi: 10.1101/sqb.2007.72.031. PMID: 18419323. Neuro/psych⚠ Cited at: §6 (psychiatric: bipolar/CLOCK histone acetylation). https://pubmed.ncbi.nlm.nih.gov/18419323/

[35] Nestler, E. J., Barrot, M., & Self, D. W. (2001). ΔFosB: A sustained molecular switch for addiction. *Proceedings of the National Academy of Sciences*, *98*(20), 11042-11046. https://doi.org/10.1073/pnas.191352698. Neuro/psych✓ verified Cited at: §6 (psychiatric: addiction/DeltaFosB epigenetic remodeling); closing synthesis. https://www.pnas.org/doi/10.1073/pnas.191352698

[36] Vialou V, Feng J, Robison AJ, Nestler EJ. Epigenetic mechanisms of depression and antidepressant action. Annu Rev Pharmacol Toxicol. 2013;53:59-87. doi: 10.1146/annurev-pharmtox-010611-134540. Epub 2012 Sep 27. PMID: 23020296; PMCID: PMC3711377. Neuro/psych⚠ Cited at: §6 (depression: HDAC5, BDNF exon IV; antidepressant mechanism). https://pubmed.ncbi.nlm.nih.gov/23020296/

[37] Chen KW, Chen L. Epigenetic Regulation of BDNF Gene during Development and Diseases. Int J Mol Sci. 2017 Mar 6;18(3):571. doi: 10.3390/ijms18030571. PMID: 28272318; PMCID: PMC5372587. Neuro/psych✓ verified Cited at: §6 (BDNF convergence — closing synthesis section). https://pubmed.ncbi.nlm.nih.gov/28272318/

[38] Peña, C. J. (2025). Epigenetic regulation of brain development, plasticity, and response to early-life stress. *Neuropsychopharmacology*, *51*(1), 5-15. https://doi.org/10.1038/s41386-025-02179-z. https://www.nature.com/articles/s41386-025-02179-z

[39] Laird, P. W. (2010). Principles and challenges of genome-wide DNA methylation analysis. *Nature Reviews Genetics*, *11*(3), 191-203. https://doi.org/10.1038/nrg2732. Tools✓ verified Cited at: §5 (tools: bisulfite sequencing — WGBS, pyrosequencing)

doi.org/10.1038/nrg2732

[40] Principles and Workflow of Whole Genome Bisulfite Sequencing. https://www.cd-genomics.com/principles-and-workflow-of-whole-genome-bisulfite-sequencing.html

[41] Madeleine Duvic† & Jenny Vu, Vorinostat- a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin. Investig. Drugs (2007) 16(7). Tools⚠ Cited at: §5 (tools: HDAC inhibitor Vorinostat — FDA approval). file:///C:/Users/Hi/Desktop/%C4%90V%20SHPT/264-Vorinostat-aneworalhistonedeacetylaseinhibitorapprovedforCTCL.pdf

[42] Derissen, E. J., Beijnen, J. H., & Schellens, J. H. (2013). Concise Drug Review: Azacitidine and Decitabine. *The Oncologist*, *18*(5), 619. https://doi.org/10.1634/theoncologist.2012-0465. Tools✓ verified Cited at: §5 (tools: DNMTi azacitidine/decitabine — MDS/AML). https://pmc.ncbi.nlm.nih.gov/articles/PMC3662854/

[43] Levine, M. E., et al., (2018). An epigenetic biomarker of aging for lifespan and healthspan. *Aging (Albany NY)*, *10*(4), 573. https://doi.org/10.18632/aging.101414. Tools✓ verified Cited at: §3 (non-

cancer table: epigenetic clocks); §5 (tools: PhenoAge clock).
https://pmc.ncbi.nlm.nih.gov/articles/PMC5940111/

[44] Marioni RE, et al., DNA methylation age of blood predicts all-cause mortality in later life. Genome Biol. 2015 Jan 30;16(1):25. doi: 10.1186/s13059-015-0584-6. PMID: 25633388; PMCID: PMC4350614. Tools✓ verified Cited at: §5 (tools: epigenetic clocks predicting mortality).
https://pubmed.ncbi.nlm.nih.gov/25633388/

[45] Tan MG, Chua WT, Esiri MM, Smith AD, Vinters HV, Lai MK. Genome wide profiling of altered gene expression in the neocortex of Alzheimer's disease. J Neurosci Res. 2010 May 1;88(6):1157-69. doi: 10.1002/jnr.22290. PMID: 19937809. Tools⚠ Cited at: §6 (neurological: Alzheimer's aging context).
https://pubmed.ncbi.nlm.nih.gov/19937809/

[46] Rajnish A. Gupta, et al., Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010 April 15; 464(7291): 1071–1076. doi:10.1038/nature08975. Cancer⚠ Cited at: §4 (ncRNA table: HOTAIR lncRNA in cancer).
file:///C:/Users/Hi/Desktop/%C4%90V%20SHPT/Long_non-coding_RNA_HOTAIR_reprograms_chromatin_st.pdf

[47] Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115. doi: 10.1186/gb-2013-14-10-r115. Erratum in: Genome Biol. 2015 May 13;16:96. doi: 10.1186/s13059-015-0649-6. PMID: 24138928; PMCID: PMC4015143. General✓ verified Cited at: §3 (non-cancer table: epigenetic clocks); §5 (Horvath clock — 353 CpG sites).
https://pubmed.ncbi.nlm.nih.gov/24138928/